An Interview With Catherine Miller, PharmD, of Intellia Therapeutics on an Experimental Gene Editing Therapy for HAE

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Catherine Miller, PharmD, global medical affairs lead for hereditary angioedema (HAE) at Intellia Therapeutics, on an experimental gene editing therapy known as lonvo-Z.